search
Back to results

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

Primary Purpose

Bacterial Infection, Anti-infective Agents, Breast Implantation

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Cefadroxil discontinued early
Cefadroxil until drain removal
Sponsored by
Stony Brook University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bacterial Infection focused on measuring Surgical Site Infection, Breast Reconstruction, Antibiotics

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • All patients presenting to Stony Brook University Medical Center Plastic Surgery clinic for immediate breast reconstruction using a tissue expander.
  • Age 18 years or older

Exclusion Criteria

  • Delayed or revision implant reconstruction
  • Refusal or inability to consent
  • Contraindications to surgery as determined by attending physician
  • Contraindications to both penicillin/cephalosporin and clindamycin antibiotics (significant allergies)
  • Patients with serious existing systemic infection, defined as 2 or more of the following:

Peripheral body temperature >38 degrees Celsius CRP >5g/L Leukocytes > 12,000/microliter

Sites / Locations

  • Stony Brook University Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Antibiotics until Drain Removal

Early discontinuation of antibiotics

Arm Description

All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.

All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.

Outcomes

Primary Outcome Measures

Surgical Site infection
One or more of the following: Purulent drainage, with or without laboratory confirmation, from the superficial incision. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture-negative. Diagnosis of superficial incisional SSI by the surgeon or attending physician.

Secondary Outcome Measures

Antibiotic Sensitivity
Assessed by documentation of an allergic or adverse sensitivity reaction including, but not limited to urticaria, itching, rash, anaphylaxis
Clostridium Difficile Colitis
C. Difficile colitis will be assessed by documented positive c. difficile toxin assay.
Antibiotic Resistance
Local wound infections will be cultured and sent for identification and susceptibility. Alternatively, pathological fluid collections will be aspirated and fluid will be sent for culture and susceptibility. Resistant strains will be documented and treated with alternative antibiotics.
Patient compliance
patients will be asked to bring antibiotics to clinic for counting to assess compliance.
Cost
Cost will be assessed by multiplying the duration of outpatient postoperative antibiotics by the cost for self-pay prescriptions.

Full Information

First Posted
November 18, 2010
Last Updated
May 12, 2014
Sponsor
Stony Brook University
Collaborators
The Plastic Surgery Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT01244698
Brief Title
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
Official Title
Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
November 2010 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Stony Brook University
Collaborators
The Plastic Surgery Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Antibiotics are used routinely in postoperative tissue expander based breast reconstruction (TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are also used routinely in immediate breast reconstruction to prevent fluid accumulation and seroma formation at the surgical sites. Antibiotics are most often prescribed as a precaution since drains can be a source for infection by creating open channels to outside contaminants. Plastic surgery patients without closed suction drainage devices are usually not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic prophylaxis is recommended for up to 24 hours only. These recommendations do not take into account the increased risk of indwelling closed suction drains. A recent survey of plastic surgeons, conducted by SBUMC investigators, (IRB# 129415) found that Plastic Surgeons are divided as to extended outpatient administration following TE breast reconstruction. The study plans to prospectively enroll patients who will undergo immediate breast reconstruction with TE or AF based breast reconstruction. Using the above data and the current protocol, the investigators will investigate the optimal antibiotic discontinuation period for these patients. The investigators hypothesize that the use of 24-hour perioperative antibiotics in TE or AF based immediate breast reconstruction with closed suction drainage, does not result in an increased infection rate compared to prolonged postoperative antibiotic administration.
Detailed Description
Background: Antibiotics are used routinely in postoperative tissue expander based breast reconstruction (TE) and autologous flap (AF) breast reconstruction procedures. Closed suction drains are also used routinely in immediate breast reconstruction to prevent fluid accumulation and seroma formation at the surgical sites. Antibiotics are most often prescribed as a precaution because drains may serve as an open channel to outside contaminants. Plastic surgery patients without closed suction drainage devices are usually not placed on prolonged postoperative antibiotics. Current preoperative surgical antibiotic prophylaxis is recommended for up to 24 hours only. These recommendations do not take into account the increased risk of indwelling closed suction drains. Current plastic surgery literature does not provide recommendations or consensus for antibiotic discontinuation following immediate breast reconstruction. A recent survey conducted of 650 plastic surgeons showed that 98% of respondents give preoperative antibiotics, while 91% provide antibiotics for up to 24 hours. Additionally, 71% of respondents prescribe postoperative outpatient antibiotics. There was a divide of when to discontinue antibiotics among plastic surgeons who gave them postoperatively. 46% preferred to continue antibiotics until drain removal, while 52% preferred a specific postoperative day, most commonly day 5 or 7. In the same survey, the majority (97%) of surgeons use IV Cefazolin as the choice for preoperative prophylaxis and oral Cephalexin (75.4%) and Cefadroxil (14.3%) for outpatient antibiotics. Currently at Stony Brook University Medical Center, patients normally receive 24 hours of IV Cefazolin, followed by postoperative antibiotic prescription for Cefadroxil. Antibiotics are discontinued when the final drain is removed. The study plans to prospectively enroll patients who will undergo immediate breast reconstruction with TE or AF based breast reconstruction. Using the above data and the current protocol, the investigators will investigate the optimal antibiotic discontinuation period for these patients. The investigators will randomize these patients into two groups. One group will receive the current antibiotic regimen of 24 hours of IV Cefazolin, followed by outpatient Cefadroxil. Antibiotics will be discontinued for this group once the final drain is removed. The other group will only receive 24 hours of IV Cefazolin without any additional outpatient antibiotics, as is recommended for elective clean surgeries. In patients with penicillin allergies or sensitivity, clindamycin, IV and oral is used. The same randomization will apply in these patients. Rationale for early discontinuation of postoperative antibiotics: Studies have associated prolonged antimicrobial prophylaxis with development of resistant bacterial strains following surgical procedures. No evidence has been reported supporting practices of continuing antibiotics until drains are removed. A single dose of preoperative IV antibiotics has been suggested to be sufficient prophylaxis for most breast surgery patients discharged home with drains.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bacterial Infection, Anti-infective Agents, Breast Implantation
Keywords
Surgical Site Infection, Breast Reconstruction, Antibiotics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
132 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Antibiotics until Drain Removal
Arm Type
Other
Arm Description
All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil until the final drain is removed. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin.
Arm Title
Early discontinuation of antibiotics
Arm Type
Experimental
Arm Description
All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics.
Intervention Type
Drug
Intervention Name(s)
Cefadroxil discontinued early
Other Intervention Name(s)
Clindamycin, Cleocin, Duricef, Ancef, Cefazolin
Intervention Description
All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
Intervention Type
Drug
Intervention Name(s)
Cefadroxil until drain removal
Other Intervention Name(s)
Duricef, Cefazolin, Ancef, Clindamycin, Cleocin
Intervention Description
All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
Primary Outcome Measure Information:
Title
Surgical Site infection
Description
One or more of the following: Purulent drainage, with or without laboratory confirmation, from the superficial incision. Organisms isolated from an aseptically obtained culture of fluid or tissue from the superficial incision. At least one of the following signs or symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superficial incision is deliberately opened by surgeon, unless incision is culture-negative. Diagnosis of superficial incisional SSI by the surgeon or attending physician.
Time Frame
365 days after the procedure
Secondary Outcome Measure Information:
Title
Antibiotic Sensitivity
Description
Assessed by documentation of an allergic or adverse sensitivity reaction including, but not limited to urticaria, itching, rash, anaphylaxis
Time Frame
From administration of the antibiotic until discontinuation
Title
Clostridium Difficile Colitis
Description
C. Difficile colitis will be assessed by documented positive c. difficile toxin assay.
Time Frame
up to 365 days postoperatively
Title
Antibiotic Resistance
Description
Local wound infections will be cultured and sent for identification and susceptibility. Alternatively, pathological fluid collections will be aspirated and fluid will be sent for culture and susceptibility. Resistant strains will be documented and treated with alternative antibiotics.
Time Frame
1 year postoperatively
Title
Patient compliance
Description
patients will be asked to bring antibiotics to clinic for counting to assess compliance.
Time Frame
while antibiotics are being administered postoperatively
Title
Cost
Description
Cost will be assessed by multiplying the duration of outpatient postoperative antibiotics by the cost for self-pay prescriptions.
Time Frame
while antibiotics are being administered postoperatively

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: All patients presenting to Stony Brook University Medical Center Plastic Surgery clinic for immediate breast reconstruction using a tissue expander. Age 18 years or older Exclusion Criteria Delayed or revision implant reconstruction Refusal or inability to consent Contraindications to surgery as determined by attending physician Contraindications to both penicillin/cephalosporin and clindamycin antibiotics (significant allergies) Patients with serious existing systemic infection, defined as 2 or more of the following: Peripheral body temperature >38 degrees Celsius CRP >5g/L Leukocytes > 12,000/microliter
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Duc T Bui, MD
Organizational Affiliation
Stony Brook University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brett T Phillips, MD
Organizational Affiliation
Stony Brook University Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Duc T Bui, MD
Organizational Affiliation
Stony Brook University Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Stony Brook University Medical Center
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11792
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27106640
Citation
Phillips BT, Fourman MS, Bishawi M, Zegers M, O'Hea BJ, Ganz JC, Huston TL, Dagum AB, Khan SU, Bui DT. Are Prophylactic Postoperative Antibiotics Necessary for Immediate Breast Reconstruction? Results of a Prospective Randomized Clinical Trial. J Am Coll Surg. 2016 Jun;222(6):1116-24. doi: 10.1016/j.jamcollsurg.2016.02.018. Epub 2016 Mar 4.
Results Reference
derived

Learn more about this trial

Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction

We'll reach out to this number within 24 hrs